-+ 0.00%
-+ 0.00%
-+ 0.00%

Mira Pharmaceuticals expands Ketamir-2 license to worldwide rights across 10 major markets

PUBT·05/27/2026 12:01:31
Listen to the news
Mira Pharmaceuticals expands Ketamir-2 license to worldwide rights across 10 major markets
  • Mira Pharmaceuticals expanded its exclusive Ketamir-2 license to worldwide rights under an amended agreement with MIRALOGX.
  • Broader IP coverage spans 10 major markets, supporting global partnering options as Ketamir-2 advances toward Phase 2a in CIPN.
  • The amendment leaves the previously disclosed core economic terms of the original license agreement largely unchanged.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202605270800ACCESSWRNAPR_____1170735) on May 27, 2026, and is solely responsible for the information contained therein.